CRP and prostate cancer: On univariate analyses (Table 1), NLR ≤ 5 (p = 0.033), LDH ≤ 250 U/L (p < 0.001), CRP ≤ 25 mg/L (p < 0.001), favorable tumor type (breast cancer and myeloma/lymphoma followed by prostate cancer, p < 0.001), being ambulatory prior to radiotherapy (p < 0.001), and normal sphincter function (p = 0.011) were significantly associated with survival.